Vinorelbine - Tablet Vinorelbine - 30mg 1 Tablet(s) / Tablet ZAS Corporation Introduction: Vinorelbine is an anti-cancer medication used in the treatment of breast cancer and non-small cell lung cancer. It is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel... Uses of Vinorelbine: Breast cancerNon-small cell lung cancer Side effects of Vinorelbine: NauseaVomitingWeaknessFatigueHair lossLow blood plateletsIncreased liver enzymesFeverAnemia (low number of red blood cells)BleedingConstipation How to use Vinorelbine: Your doctor or nurse will give you this medicine. Kindly do not self administer. How Vinorelbine works: Vinorelbine blocks replication of genetic material (DNA) in the cancer cells. Thus it stops the growth and multiplication of cancer cells. Indication: Breast cancer, Ovarian cancer, Cervical cancer, Non-small cell lung cancer Administration: IV Preparation May be diluted in syringe or bag Syringe: dilute to 1.5-3 mg/mL in NS or D5W IV Bag: dilute to 0.5-2 mg/mL in NS, 1/2NS, D5W, D5/½NS, LR or Ringer's IV Administration Administer IV over 6-10 min through sidearm of free-flowing IV closest to IV bag Then flush with 75-125 mL of one of the IV fluids Adult Dose: Oral Non-small cell lung cancer Adult: 60 mg/m2once wkly for 3 wk, may increase subsequently to 80 mg/m2 once wkly. If neutrophil count is 75% of liver volume replaced by the tumour): Decrease dose by 1/3. Bilirubin 2.1-3 mg/100 ml: Reduce IV dose by 50%. Bilirubin >3 mg/100 ml: Reduce IV dose by 75%. Intravenous Non-small cell lung cancer Adult: As single agent: 30 mg/m2 wkly as infusion over 20-30 minutes (after diluting in 125 ml normal saline or glucose 5%) or as slow bolus over 5-10 minutes (after diluting in 20-50 ml normal saline or glucose 5%). Delay subsequent... Contraindication: Hypersensitivity to vinorelbine or other vinca alkaloids; severe current or recent infection (within last 2 wk); neutropenia; thrombocytopenia; severe hepatic impairment. Intrathecal admin. Do not give concomitantly with radiotherapy if liver is in treatment field. Pregnancy, lactation. Mode of Action: Vinorelbine, a semisynthetic vinblastine derivative, binds to tubulin and inhibits microtubule formation. This disrupts the formation of the mitotic spindle thereby arresting the cell at metaphase. Precaution: Hepatic impairment. Compromised bone marrow reserve due to prior irradiation or chemotherapy; recovering marrow function from the effects of previous chemotherapy. Prior radiation therapy; past history or pre-existing neuropathy. CBC with differentials to be monitored prior to admin of subsequent doses. Delay subsequent doses, if neutrophil count < 2000 cells/mm3. Each admin to be followed by at least 250 ml of normal saline to flush the vein. Avoid extravasation. If extravasation occurs, stop infusion immediately, and flush the vein with normal saline solution; admin the remaining solution in another vein. Do not father a child during and up to six... Side Effect: >10% Leukopenia (92%),Granulocytopenia (90%),Anemia (83%),Elev AST (67%),Nausea (44%),Asthenia (36%),Constipation (35%),Fatigue (27%),Peripheral neuropathy (25%),Vomiting (20%),Anorexia (20%),Stomatitis (20%),Alopecia (12%) 1-10% Dyspnea (7%),Chest pain (5%),Rash (5%),SOB (3%),Hemorrhagic cystitis (1%),SIADH (1%) Interaction: Increased risk of granulocytopenia with cisplatin. Increased risk of neurotoxicity with paclitaxel, itraconazole, ketoconazole. Increased radiosensitising effects with prior or concomitant radiation therapy. Increased pulmonary toxicity with mitomycin. Increased myelotoxicity with zidovudine. Earlier onset and/or an increased severity of side effects with CYP3A inhibitors. Possible increase in vincristine levels with aprepitant. Possible infection with live vaccines.